UK Research and Innovation’s (UKRI) Medical Research Council (MRC) is investing £2 million to support research into cancers with poor survival rates. These include studies into cancers of the brain, lung and oesophagus.
As part of its £650m ‘Life Sci for Growth’ scheme to boost the life sciences sector and the wider economy, the government will establish a Medicines Manufacturing Skills Centre of Excellence with a dedicated £5.5m fund.
Britain’s life science community is celebrating the country’s return to the EU Horizon Europe research programme, which was announced on 7 September 2023.
Roadblocks from the EU, and the UK government’s determination to get a ‘fair settlement’ on associate membership, are harming international collaborative research programmes and, ultimately, patients’ access to innovative treatments and devices.
Draft legislation has been published by the UK government on a proposed merged R&D tax relief scheme. If implemented, the reform would affect companies claiming R&D tax relief under either the Research and Development Expenditure Credit (RDEC) or the small or medium enterprises (SME) R&D relief.
The National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC) are investing £14 million in a new research programme to investigate challenges in the diagnosis, management and treatment of rare diseases.
The World Health Organization (WHO) has published a report outlining 40 research topics that should be prioritised by scientists around the world to help fight antimicrobial resistance (AMR). The goal is that results will be forthcoming by 2030, which will feed into policies and interventions to combat AMR.
We are excited to report that PharmaMedic's Managing Director, Dr Malcolm Barratt-Johnson has received a Global Fellow in Medicines Development (GFMD) award from the respected GMDP Academy.
Decentralised clinical trials (DCTs) are being used increasingly in the pharma industry for clinical research and the US Food and Drug Administration (FDA) has published draft guidance for those carrying out trials at non-traditional investigation sites.
Cancer diagnosis and treatment are set to be accelerated with the opening of England’s first Integrated Pathology Unit (IPU). The new facility will apply pioneering digital imaging and artificial intelligence to pathology, assisting clinical trial research programmes focused on developing tests for cancer.
